Newer Oral Anticoagulant Agents: A New Era in Medicine

被引：12

作者：

Goel, Ramil ^{[1
]}

Srivathsan, Komandoor ^{[1
]}

机构：

[1] Mayo Clin, Div Cardiovasc Dis, Phoenix, AZ 85054 USA

来源：

CURRENT CARDIOLOGY REVIEWS | 2012年 / 8卷 / 02期

关键词：

Acute coronary syndrome; apixaban; atrial fibrillation; dabigatran; deep venous thrombosis; pulmonary embolism; rivaroxaban; venous thromboembolism;

D O I：

10.2174/157340312801784934

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

After a gap of almost 60 years following the development of warfarin, 2 new categories of oral anticoagulant agents have been approved for clinical use - the direct thrombin inhibitors and factor Xa inhibitors. These agents promise to be more convenient to administer with fixed dosing but still have equivalent efficacy and improved bleeding risk compared to warfarin. The clinical community is looking forward to the widespread usage of these agents but there is also some apprehension regarding bleeding risks, non-availability of specific reversal strategies and lack of specific monitoring parameters. This review article will attempt to educate the reader about three representative drugs from these classes: Dabigatran, Rivaroxaban and Apixaban. We will discuss the historical perspective to the development of these drugs, available research data and pharmacology of these agents. The best strategies for monitoring and reversal of these drugs in special situations will also be touched upon.

引用

页码：158 / 165

页数：8

共 38 条

[1]

Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome [J].

Alexander, John H. ;

Lopes, Renato D. ;

James, Stefan ;

Kilaru, Rakhi ;

He, Yaohua ;

Mohan, Puneet ;

Bhatt, Deepak L. ;

Goodman, Shaun ;

Verheugt, Freek W. ;

Flather, Marcus ;

Huber, Kurt ;

Liaw, Danny ;

Husted, Steen E. ;

Lopez-Sendon, Jose ;

De Caterina, Raffaele ;

Jansky, Petr ;

Darius, Harald ;

Vinereanu, Dragos ;

Cornel, Jan H. ;

Cools, Frank ;

Atar, Dan ;

Luis Leiva-Pons, Jose ;

Keltai, Matyas ;

Ogawa, Hisao ;

Pais, Prem ;

Parkhomenko, Alexander ;

Ruzyllo, Witold ;

Diaz, Rafael ;

White, Harvey ;

Ruda, Mikhail ;

Geraldes, Margarida ;

Lawrence, Jack ;

Harrington, Robert A. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08) :699-708

[2]

Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial [J].

Alexander, John H. ;

Becker, Richard C. ;

Bhatt, Deepak L. ;

Cools, Frank ;

Crea, Filippo ;

Dellborg, Mikael ;

Fox, Keith A. A. ;

Goodman, Shaun G. ;

Harrington, Robert A. ;

Huber, Kurt ;

Husted, Steen ;

Lewis, Basil S. ;

Lopez-Sendon, Jose ;

Mohan, Puneet ;

Montalescot, Gilles ;

Ruda, Mikhail ;

Ruzyllo, Witold ;

Verheugt, Freek ;

Wallentin, Lars ;

Darius, Harald ;

Simoons, Maarten ;

Boersma, Eric ;

DeLemos, James ;

Spencer, Fred .

CIRCULATION, 2009, 119 (22) :2877-U39

[3]

MORTALITY IN PATIENTS TREATED FOR PULMONARY-EMBOLISM [J].

ALPERT, JS ;

SMITH, R ;

CARLSON, CJ ;

OCKENE, IS ;

DEXTER, L ;

DALEN, JE .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1976, 236 (13) :1477-1480

[4]

BARRITT DW, 1960, LANCET, V1, P1309

[5]

Oral Rivaroxaban for Symptomatic Venous Thromboembolism. [J].

Bauersachs, Rupert ;

Berkowitz, Scott D. ;

Brenner, Benjamin ;

Buller, Harry R. ;

Decousus, Herve ;

Gallus, Alex S. ;

Lensing, Anthonie W. ;

Misselwitz, Frank ;

Prins, Martin H. ;

Raskob, Gary E. ;

Segers, Annelise ;

Verhamme, Peter ;

Wells, Phil ;

Agnelli, Giancarlo ;

Bounameaux, Henri ;

Cohen, Alexander ;

Davidson, Bruce L. ;

Piovella, Franco ;

Schellong, Sebastian .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) :2499-2510

[6]

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate* [J].

Blomback, Margareta ;

He, Shu ;

Bark, Niklas ;

Wallen, Hakan N. ;

Elg, Margareta .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (06) :758-765

[7]

Apixaban in Patients with Atrial Fibrillation [J].

Connolly, Stuart J. ;

Eikelboom, John ;

Joyner, Campbell ;

Diener, Hans-Christoph ;

Hart, Robert ;

Golitsyn, Sergey ;

Flaker, Greg ;

Avezum, Alvaro ;

Hohnloser, Stefan H. ;

Diaz, Rafael ;

Talajic, Mario ;

Zhu, Jun ;

Pais, Prem ;

Budaj, Andrzej ;

Parkhomenko, Alexander ;

Jansky, Petr ;

Commerford, Patrick ;

Tan, Ru San ;

Sim, Kui-Hian ;

Lewis, Basil S. ;

Van Mieghem, Walter ;

Lip, Gregory Y. H. ;

Kim, Jae Hyung ;

Lanas-Zanetti, Fernando ;

Gonzalez-Hermosillo, Antonio ;

Dans, Antonio L. ;

Munawar, Muhammad ;

O'Donnell, Martin ;

Lawrence, John ;

Lewis, Gayle ;

Afzal, Rizwan ;

Yusuf, Salim .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (09) :806-817

[8]

Dabigatran versus Warfarin in Patients with Atrial Fibrillation. [J].

Connolly, Stuart J. ;

Ezekowitz, Michael D. ;

Yusuf, Salim ;

Eikelboom, John ;

Oldgren, Jonas ;

Parekh, Amit ;

Pogue, Janice ;

Reilly, Paul A. ;

Themeles, Ellison ;

Varrone, Jeanne ;

Wang, Susan ;

Alings, Marco ;

Xavier, Denis ;

Zhu, Jun ;

Diaz, Rafael ;

Lewis, Basil S. ;

Darius, Harald ;

Diener, Hans-Christoph ;

Joyner, Campbell D. ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (12) :1139-1151

[9]

Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects [J].

Eerenberg, Elise S. ;

Kamphuisen, Pieter W. ;

Sijpkens, Meertien K. ;

Meijers, Joost C. ;

Buller, Harry R. ;

Levi, Marcel .

CIRCULATION, 2011, 124 (14) :1573-1579

[10]

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement:: the RE-MODEL randomized trial [J].

Eriksson, B. I. ;

Dahl, O. E. ;

Rosencher, N. ;

Kurth, A. A. ;

Van Dijk, N. ;

Frostick, S. P. ;

Kalebo, P. ;

Christiansen, A. V. ;

Hantel, S. ;

Hettiarachchi, R. ;

Schnee, J. ;

Buller, H. R. .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (11) :2178-2185

← 1 2 3 4 →